The Biden administration announced Thursday that drug companies receiving research funding from HHS’ emergency response arm, the Administration for Strategic Preparedness and Response, will have to commit to a “fair price” – not more than they charge in other countries. Host Chelsea Cirruzzo talks with POLITICO health care reporter Robert King about the Biden administration's efforts to curb high prescription drug prices.
The two big ways AI is changing health care
For HHS, AI is an inside job
A look back at abortion policy in 2023 and a look forward to 2024
Fentanyl’s fatal year in review
What the USPS is hiding about worker safety
Congress’ health reform package: Where does it stand?
The future of milestone opioid law
How the coming mining boom could upend local health care
Why Congress is deadlocked over PEPFAR
Some drug patents in the Biden administration's crosshairs
Who’s calling the shots on health care policy now?
Dr. Google’s legislative test
Repeal-and-replace redux
Sickle cell gene-editing treatment poised for FDA approval
Trump reignites Affordable Care Act battle
The changing face of primary care
China’s virus outbreak: Seasonal return or new threat?
Medicare Advantage plans on the rise, and under scrutiny
Organ transplant reforms stalled by lack of funding
Create your
podcast in
minutes
It is Free